467 related articles for article (PubMed ID: 18006614)
41. Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer.
Francis DL; Visvikis D; Costa DC; Arulampalam TH; Townsend C; Luthra SK; Taylor I; Ell PJ
Eur J Nucl Med Mol Imaging; 2003 Jul; 30(7):988-94. PubMed ID: 12739071
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic performance of ¹⁸F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with ¹⁸F-fluorodeoxyglucose PET/CT.
Nakajo M; Nakajo M; Kajiya Y; Jinguji M; Nishimata N; Shimaoka S; Nihara T; Aridome K; Tanaka S; Fukukura Y; Tani A; Koriyama C
Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1223-32. PubMed ID: 23653240
[TBL] [Abstract][Full Text] [Related]
43. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3'-deoxy-3'-18F-fluorothymidine and 18F-FDG.
Tian J; Yang X; Yu L; Chen P; Xin J; Ma L; Feng H; Tan Y; Zhao Z; Wu W
J Nucl Med; 2008 Feb; 49(2):186-94. PubMed ID: 18199618
[TBL] [Abstract][Full Text] [Related]
44. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.
Yun M; Choi HS; Yoo E; Bong JK; Ryu YH; Lee JD
J Nucl Med; 2005 Jun; 46(6):953-7. PubMed ID: 15937305
[TBL] [Abstract][Full Text] [Related]
45. Comparison of 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours.
Herrmann K; Erkan M; Dobritz M; Schuster T; Siveke JT; Beer AJ; Wester HJ; Schmid RM; Friess H; Schwaiger M; Kleeff J; Buck AK
Eur J Nucl Med Mol Imaging; 2012 May; 39(5):846-51. PubMed ID: 22278320
[TBL] [Abstract][Full Text] [Related]
46. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response.
Gerbaudo VH; Killoran JH; Kim CK; Hornick JL; Nowak JA; Enzinger PC; Mamon HJ
Ann Nucl Med; 2018 Apr; 32(3):165-174. PubMed ID: 29332233
[TBL] [Abstract][Full Text] [Related]
47. Primary Tumor ¹⁸F-FDG Avidity Affects the Performance of ¹⁸F-FDG PET/CT for Detecting Gastric Cancer Recurrence.
Kim SJ; Cho YS; Moon SH; Bae JM; Kim S; Choe YS; Kim BT; Lee KH
J Nucl Med; 2016 Apr; 57(4):544-50. PubMed ID: 26678615
[TBL] [Abstract][Full Text] [Related]
48. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer.
Yamamoto Y; Nishiyama Y; Kimura N; Ishikawa S; Okuda M; Bandoh S; Kanaji N; Asakura M; Ohkawa M
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):236-45. PubMed ID: 17909790
[TBL] [Abstract][Full Text] [Related]
49. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
50. Changes in (18)F-fluorothymidine and (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy.
Hoshikawa H; Mori T; Kishino T; Yamamoto Y; Inamoto R; Akiyama K; Mori N; Nishiyama Y
Ann Nucl Med; 2013 May; 27(4):363-70. PubMed ID: 23378102
[TBL] [Abstract][Full Text] [Related]
51. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas.
Tripathi M; Sharma R; D'Souza M; Jaimini A; Panwar P; Varshney R; Datta A; Kumar N; Garg G; Singh D; Grover RK; Mishra AK; Mondal A
Clin Nucl Med; 2009 Dec; 34(12):878-83. PubMed ID: 20139821
[TBL] [Abstract][Full Text] [Related]
52. [18F]FLT PET for diagnosis and staging of thoracic tumours.
Dittmann H; Dohmen BM; Paulsen F; Eichhorn K; Eschmann SM; Horger M; Wehrmann M; Machulla HJ; Bares R
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1407-12. PubMed ID: 12898201
[TBL] [Abstract][Full Text] [Related]
53. A pilot study of the diagnostic and prognostic values of FLT-PET/CT for pancreatic cancer: comparison with FDG-PET/CT.
Nakajo M; Kajiya Y; Tani A; Jinguji M; Nakajo M; Nihara T; Fukukura Y; Yoshiura T
Abdom Radiol (NY); 2017 Apr; 42(4):1210-1221. PubMed ID: 27891549
[TBL] [Abstract][Full Text] [Related]
54. Comparison of
Mori M; Fujioka T; Ichikawa R; Inomata R; Katsuta L; Yashima Y; Yamaga E; Tsuchiya J; Hayashi K; Kumaki Y; Oda G; Nakagawa T; Onishi I; Kubota K; Tateishi U
Tomography; 2022 Oct; 8(5):2533-2546. PubMed ID: 36287810
[TBL] [Abstract][Full Text] [Related]
55. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings.
Stahl A; Ott K; Weber WA; Becker K; Link T; Siewert JR; Schwaiger M; Fink U
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):288-95. PubMed ID: 12552348
[TBL] [Abstract][Full Text] [Related]
56. Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor.
Hong IK; Kim JH; Ra YS; Kwon DH; Oh SJ; Kim JS
J Comput Assist Tomogr; 2011; 35(6):679-84. PubMed ID: 22082535
[TBL] [Abstract][Full Text] [Related]
57. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.
Giammarile F; Billotey C; Lombard-Bohas C; Le Bars D; Bournaud C; Masson S; Walter T; Houzard C; Scoazec JY; Hervieu V; Vuillez JP; Cornu C; Janier M; Borson-Chazot F
Nucl Med Commun; 2011 Feb; 32(2):91-7. PubMed ID: 21076344
[TBL] [Abstract][Full Text] [Related]
58. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
Buck AK; Herrmann K; Büschenfelde CM; Juweid ME; Bischoff M; Glatting G; Weirich G; Möller P; Wester HJ; Scheidhauer K; Dechow T; Peschel C; Schwaiger M; Reske SN
Clin Cancer Res; 2008 May; 14(10):2970-7. PubMed ID: 18445694
[TBL] [Abstract][Full Text] [Related]
59. A pilot study for texture analysis of
Nakajo M; Kajiya Y; Tani A; Jinguji M; Nakajo M; Kitazono M; Yoshiura T
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2158-2168. PubMed ID: 28770274
[TBL] [Abstract][Full Text] [Related]
60. (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.
Brepoels L; Stroobants S; Verhoef G; De Groot T; Mortelmans L; De Wolf-Peeters C
J Nucl Med; 2009 Jul; 50(7):1102-9. PubMed ID: 19525456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
